(Q43758596)

26 November 2017

title

Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis (English)

1 reference

26 November 2017

1 reference

Y S de Boer

1

1 reference

26 November 2017

N M F van Gerven

2

1 reference

26 November 2017

N K H de Boer

3

1 reference

26 November 2017

C J J Mulder

4

1 reference

26 November 2017

G Bouma

5

1 reference

26 November 2017

C M J van Nieuwkerk

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

24 January 2013

1 reference

Alimentary Pharmacology & Therapeutics

26 November 2017

published in

1 reference

26 November 2017

volume

37

1 reference

26 November 2017

issue

6

1 reference

26 November 2017

page(s)

640-646

1 reference

Diagnosis and management of autoimmune hepatitis

26 November 2017

cites work

1 reference

Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD

21 January 2018

1 reference

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

21 January 2018

1 reference

Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease

21 January 2018

1 reference

Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods

21 January 2018

1 reference

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

21 January 2018

1 reference

Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis.

21 January 2018

1 reference

Advances in the current treatment of autoimmune hepatitis

21 January 2018

1 reference

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

21 January 2018

1 reference

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

21 January 2018

1 reference

Cost-effectiveness of pharmacotherapy for autoimmune hepatitis

21 January 2018

1 reference

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12223

1 reference

26 November 2017

1 reference